These findings are consistent with those of Müller et al. [30], who showed that the expression of class 1 HDAC isoenzymes is deregulated in breast cancer samples, and that varying expression levels of HDAC1, HDAC2 and HDAC3 correlated with clinicopathological parameters. This evidence concerns the gene HDAC3 and breast cancer.